Search
forResearch 10 of 54
- Temperature-dependent phase transition microemulsions for enhanced transdermal delivery of finasteride and silodosin
- Simultaneous Quantification of Dutasteride and Silodosin Using a Stability-Indicating RP-HPLC Approach
- Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
- Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice
- PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY
- The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →